EULAR NEWS: Deucravacitinib (Sotyktu, BMS) Performs Well in Adults With PsA
Significantly more psoriatic arthritis (PsA) patients treated with deucravacitinib (Sotyktu, BMS) achieved at least a 20 percent improvement in signs and symptoms of disease (American College of Rheumatology [ACR] 20) compared with placebo at Week 16, according to new data from the Phase 3 POETYK PsA-1 trial presented at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain.